Journal of Dermatological Treatment (Dec 2023)

A hyaluronic acid-based micro-filler improves superficial wrinkles and skin quality: a randomized prospective controlled multicenter study

  • Ferial Fanian,
  • Jean-Jacques Deutsch,
  • Marie Thérèse Bousquet,
  • Sylvie Boisnic,
  • Pierre Andre,
  • Isabelle Catoni,
  • Ghislaine Beilin,
  • Christian Lemmel,
  • Maryna Taieb,
  • Marie Gomel-Toledano,
  • Hanane Issa,
  • Philippe Garcia

DOI
https://doi.org/10.1080/09546634.2023.2216323
Journal volume & issue
Vol. 34, no. 1

Abstract

Read online

Background NCTF®135HA is a bio-revitalizing solution containing hyaluronic acid designed to compensate for skin dehydration, fatigue, and fine wrinkles associated with endogenous and environmental aging. Methods We conducted a randomized, active-controlled study to evaluate the efficacy and tolerability of NCTF®135HA injections on the face (crow’s feet), neck, and décolleté regions. Subjects were randomly assigned (3:1) to receive three NCTF®135HA treatment sessions plus twice-daily anti-aging moisturizer cream or cream alone (control). The primary outcome was the reduction in superficial wrinkles between baseline and Day (D)75 in the three areas, assessed by profilometric measures, clinical scoring, subjective changes, and tolerability. Results 146 subjects were randomized to NCTF®135HA (n = 107) or control (n = 38). At D75 and D120, NCTF®135HA significantly reduced wrinkles in all three areas and improved facial radiance scores compared with the control. Skin hydration significantly increased 7 d after the last NCTF®135HA injection. Self-esteem scales showed statistically significant improvements at D75 and D120 in subjects treated with NCTF®135HA versus baseline. Most adverse events were mild, resolved within 48 h, and were related to the injection procedure. Conclusion NCTF®135HA is an effective and well-tolerated treatment to reduce the skin signs of aging. The results are significantly superior to a routine anti-aging cream alone. (Funded by Laboratories FILLMED; ID-RCB number: 2018-A03167-48; clinicaltrials.gov number: NCT05609617)

Keywords